DS Healthcare Group (OTCMKTS: DSKX) is one of 28 public companies in the “Personal Products” industry, but how does it contrast to its competitors? We will compare DS Healthcare Group to similar companies based on the strength of its dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.
Institutional & Insider Ownership
0.0% of DS Healthcare Group shares are owned by institutional investors. Comparatively, 56.7% of shares of all “Personal Products” companies are owned by institutional investors. 19.4% of DS Healthcare Group shares are owned by insiders. Comparatively, 15.4% of shares of all “Personal Products” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a summary of current ratings and target prices for DS Healthcare Group and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|DS Healthcare Group||0||0||0||0||N/A|
|DS Healthcare Group Competitors||363||1263||1506||24||2.38|
As a group, “Personal Products” companies have a potential upside of 11.27%. Given DS Healthcare Group’s competitors higher possible upside, analysts plainly believe DS Healthcare Group has less favorable growth aspects than its competitors.
This table compares DS Healthcare Group and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|DS Healthcare Group||-62.31%||-1,304.25%||-117.85%|
|DS Healthcare Group Competitors||3.13%||87.59%||1.92%|
Risk and Volatility
DS Healthcare Group has a beta of 2.3, suggesting that its share price is 130% more volatile than the S&P 500. Comparatively, DS Healthcare Group’s competitors have a beta of 1.24, suggesting that their average share price is 24% more volatile than the S&P 500.
Earnings & Valuation
This table compares DS Healthcare Group and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|DS Healthcare Group||$12.95 million||-$6.93 million||-0.04|
|DS Healthcare Group Competitors||$16.34 billion||$2.21 billion||339.85|
DS Healthcare Group’s competitors have higher revenue and earnings than DS Healthcare Group. DS Healthcare Group is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
DS Healthcare Group competitors beat DS Healthcare Group on 7 of the 9 factors compared.
About DS Healthcare Group
DS Healthcare Group, Inc., doing business as DS Laboratories, is a personal care, product development and marketing company. The Company develops and markets branded personal care products that address thinning hair conditions, skin care and other personal care needs. It develops technologies and products for hair care and personal care needs. Its technologies include Liposome Technology, which acts as a carrier agent, and is designed to enhance the act ion of the active ingredients in its products, and Nanosome Technology, which acts as a delivery vehicle, and is designed to infuse active compounds into targeted cells. The Company products are primarily sold under its DS Laboratories brand. It also sells certain products under its Polaris Labs and Sigma Skin brands. It markets and sells these products through salons, spas, department stores, specialty retailers and distributors. The Company offers products under three product categories: Hair Care, Skin Care and Personal Care.
Receive News & Ratings for DS Healthcare Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DS Healthcare Group and related companies with MarketBeat.com's FREE daily email newsletter.